Abstract
Raloxifene hydrochloride (RLX) is a selective Estrogen-receptor modulator used to treat osteoporosis as well as breast and endometrial cancer prevention. The bioavailability of RLX is only 2% due to substantial pre-systemic clearance. The goal of this research was to customise and characterise RLX-loaded self-nanoemulsifying drug-delivery systems (SNEDDS) by using bioactive excipients that impact drug metabolism. The droplet size, zeta potential and drug content determination of optimized formulation (F-06) was found to be 147.5 nm, -28.8, 99.67% respectively. The drug release study from the nano formulation was studied in Phosphate buffer 6.8 for all the formulations F1,F2,F3,F4,F5,F6 and F7. The optimized formulation was found to be F6
 Keywords: Raloxifene hydrochloride, nanoemulsion, SNEDDS
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
